Monster's record momentum contrasts sharply with Bassett's estimate cuts, while HOOD, IBKR and TW showcase divergent paths in trading-platform innovation.
KYMR gains momentum as the FDA grants Fast Track to KT-621 for moderate to severe atopic dermatitis, boosting the stock and advancing its Type 2 pipeline.